Bioventus Inc. (BVS)
NASDAQ: BVS · Real-Time Price · USD
6.98
-0.31 (-4.25%)
Aug 7, 2025, 1:02 PM - Market open
Bioventus Revenue
Bioventus had revenue of $147.66M in the quarter ending June 28, 2025, a decrease of -2.35%. This brings the company's revenue in the last twelve months to $564.14M, up 5.08% year-over-year. In the year 2024, Bioventus had annual revenue of $573.28M with 11.89% growth.
Revenue (ttm)
$564.14M
Revenue Growth
+5.08%
P/S Ratio
0.85
Revenue / Employee
$606,604
Employees
930
Market Cap
463.18M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 573.28M | 60.94M | 11.89% |
Dec 31, 2023 | 512.35M | 228.00K | 0.04% |
Dec 31, 2022 | 512.12M | 81.22M | 18.85% |
Dec 31, 2021 | 430.90M | 109.74M | 34.17% |
Dec 31, 2020 | 321.16M | -18.98M | -5.58% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Novo Nordisk | 49.11B |
Eli Lilly and Company | 49.00B |
BVS News
- 12 hours ago - Bioventus Inc. (BVS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Bioventus Reports Second Quarter Financial Results - GlobeNewsWire
- 3 days ago - Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity - GlobeNewsWire
- 8 days ago - Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products - GlobeNewsWire
- 8 days ago - Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 3 months ago - Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Bioventus Reports First Quarter Financial Results - GlobeNewsWire
- 3 months ago - Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025 - GlobeNewsWire